BioTuesdays

Category - Markets

CymaBay Therapeutics

HCW upgrades CymaBay to buy

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on...

Mateon Therapeutics

Maxim starts Mateon at buy

Maxim Group initiated coverage of Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and 12-month price target of $2. The stock was quoted at 42 cents at midday on Jan. 27. Analyst Jason Kolbert writes that...

Adocia

Leerink downgrades Adocia to market perform

Leerink downgraded Adocia (NXT PA:ADOC.FP) to “market perform” and slashed its price target to €15.00 from €82.00 after Eli Lilly terminated its collaboration for Adocia’s ultra-fast insulin product, BioChaperone Lispro...

Athersys Logo

Athersys prices $20-million stock offering

Athersys (NASDAQ:ATHX) priced a public offering of 19,802,000 common shares at a price of $1.01 each for gross proceeds of about $20-million and gave underwriters an option to purchase up to an additional 2,970,300...

Heska

Feltl ups Heska price target to $97

Feltl reiterated a “strong buy” rating for Heska (NASDAQ:HSKA) and raised its price target to $97 from $67 on an increased valuation multiple reflecting Heska’s improved positioning. The stock was quoted at $76.46 near...

ADMA Biologics Logo

Maxim upgrades ADMA Biologics to buy

Maxim Group upgraded ADMA Biologics (NASDAQ:ADMA) to ‘buy” from “hold” and established a price target of $13 after the company agreed to acquire Biotest Pharmaceuticals’ immunoglobulin manufacturing facility in Florida...

Palatin Technologies Logo

Roth resumes coverage of Palatin, AmpliPhi, Pharming

Roth Capital Partners resumed coverage of Palatin Technologies (NYSE MKT: PTN), AmpliPhi Biosciences (NYSE MKT:APHB) and Pharming Group NV (OTC:PHGUF) with “buy” ratings and price targets of $1.50, $3 and €1.50...

Bellerophon Therapeutics

HCW starts Bellerophon Therapeutics at buy

H.C. Wainwright initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and price target of $5. The stock closed at 67 cents on Jan. 20. Bellerophon develops products for the treatment of...

Trevena

HCW starts Trevena at buy

H.C. Wainwright initiated coverage of Trevena (NASDAQ:TRVN) with a “buy” rating and $11 price target. The shares were changing hands at $6.85 at mid-day on Jan. 9. “We believe Trevena’s lead drug, oliceridine...

Natera

Canaccord starts Natera at buy

Canaccord Genuity initiated coverage of Natera (NASDAQ:NTRA) with a “buy” rating and $18 price target. The stock is changing hands at $11.66 in afternoon trading on Jan. 6. Natera is the market leader in the $2.5...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.